Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Linagliptin as a Modulator of Vascular Inflammation in Patients With Type 2 Diabetes Mellitus

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02077309
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:36.660014+00:00
Published At
2017-04-12T00:00:00+00:00
Record Updated At
2017-04-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Diabetes Mellitus Type 2 (T2DM)", "Vascular Inflammation", "Plaque Morphology"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-04-12"
protocolSection.identificationModule.nctId
"NCT02077309"
protocolSection.identificationModule.officialTitle
"Linagliptin as a Modulator of Vascular Inflammation in Patients With Type 2 Diabetes Mellitus"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Diabetes Mellitus Type 2 (T2DM) (protocolSection.conditionsModule.conditions)
  • Vascular Inflammation (protocolSection.conditionsModule.conditions)
  • Plaque Morphology (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.